All In Biotech

Drug Trial Radar · NCT02273726

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis

Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 741 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

741

Actual

Start

Jan 15, 2015

Primary completion

Sep 19, 2018

Study completion Sep 19, 2018

Sponsor

Lead sponsor
Kyntra BioIndustry
Sponsor type
Industry
Collaborators
Astellas Pharma Europe B.V.; AstraZeneca
First posted
Oct 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.

Conditions

  • CKD Anemia in Stable Dialysis Patients

Interventions

  • Epoetin AlfaDrug

    Epoetin alfa will be administered per dose and schedule specified in the arm.

  • RoxadustatDrug

    Roxadustat will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue TherapyTime frame: Baseline (Day 1, Week 0), Weeks 28 to 52
  2. Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original ProtocolTime frame: Baseline (Day 1, Week 0), Weeks 28 to 36

Locations

76 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Center

    Phoenix, Arizona

  • Research Center

    Pine Bluff, Arkansas

  • Research Center

    Chula Vista, California

  • Research Center

    Chula Vista, California

  • Research Center

    La Mesa, California

  • Research Center

    Long Beach, California

  • Research Center

    Long Beach, California

  • Research Center

    Los Angeles, California

  • Research Center

    Northridge, California

  • Research Center

    Ontario, California

  • Research Center

    Roseville, California

  • Research Center

    San Diego, California

  • Research Center

    San Dimas, California

  • Research Center

    San Gabriel, California

  • Research Center

    Whittier, California

  • Research Center

    Coral Springs, Florida

  • Research Center

    Lauderdale Lakes, Florida

  • Research Center

    Miami, Florida

  • Research Center

    Miami, Florida

  • Research Center

    Pembroke Pines, Florida

  • Research Center

    Tampa, Florida

  • Research Center

    Albany, Georgia

  • Research Center

    Meridian, Idaho

  • Research Center

    Shreveport, Louisiana

  • Research Center

    Springfield, Massachusetts

  • Research Center

    Detroit, Michigan

  • Research Center

    Detroit, Michigan

  • Research Center

    Pontiac, Michigan

  • Research Center

    Brookhaven, Mississippi

  • Research Center

    Columbus, Mississippi

  • Research Center

    Gulfport, Mississippi

  • Research Center

    Tupelo, Mississippi

  • Research Center

    Creve Coeur, Missouri

  • Research Center

    Kansas City, Missouri

  • Research Center

    Saint Ann, Missouri

  • Research Center

    St Louis, Missouri

  • Research Center

    Portsmouth, New Hampshire

  • Research Center

    North Brunswick, New Jersey

  • Research Center

    Albuquerque, New Mexico

  • Research Center

    Gallup, New Mexico

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.